{"title":"ASXL1 Gene in AML.","authors":"Rodrigo Hurtado, Fabian Guirales, Carlos A Tirado","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The ASXL1 (additional sex combs like 1) gene on 20q11 codifies the ASXL1 protein that belongs to protein complexes that play a role in gene expression and epigenetic regulation. ASXL1 is located near the DNMT3B gene and is part of a family of three genes (ASXL1, ASXL2, ASXL3) that are homologues to the Drosophila Asx gene. The ASXL1 gene contains a total of 14 exons and is expressed in the vast majority of hematopoietic cell types. While the specific job of ASXL1 in normal hematopoiesis and the involvement of mutated ASXL1 to the progression of hematopoietic malignancies have not yet been fully set forth, current data studies propose that ASXL1 is characterized as a tumor suppressor gene. Mutations in the ASXL1 gene are observed in myeloid malignancies usually associated with aggressiveness and poor clinical results and were reported first in the year 2009 in myelodysplastic syndromes (MDS). Nevertheless, ASXL1 gene mutations are also found in acute myeloid leukemia (AML) with normal karyotype as well as AML with myelodysplasia-related changes and AML with non-characteristic cytogenetic findings. Herein we examine the involvement of the ASXL1 gene in AML to address the importance of these ASXL1 mutations in the prognostic evaluation of AML.</p>","PeriodicalId":73975,"journal":{"name":"Journal of the Association of Genetic Technologists","volume":"47 2","pages":"60-68"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Association of Genetic Technologists","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The ASXL1 (additional sex combs like 1) gene on 20q11 codifies the ASXL1 protein that belongs to protein complexes that play a role in gene expression and epigenetic regulation. ASXL1 is located near the DNMT3B gene and is part of a family of three genes (ASXL1, ASXL2, ASXL3) that are homologues to the Drosophila Asx gene. The ASXL1 gene contains a total of 14 exons and is expressed in the vast majority of hematopoietic cell types. While the specific job of ASXL1 in normal hematopoiesis and the involvement of mutated ASXL1 to the progression of hematopoietic malignancies have not yet been fully set forth, current data studies propose that ASXL1 is characterized as a tumor suppressor gene. Mutations in the ASXL1 gene are observed in myeloid malignancies usually associated with aggressiveness and poor clinical results and were reported first in the year 2009 in myelodysplastic syndromes (MDS). Nevertheless, ASXL1 gene mutations are also found in acute myeloid leukemia (AML) with normal karyotype as well as AML with myelodysplasia-related changes and AML with non-characteristic cytogenetic findings. Herein we examine the involvement of the ASXL1 gene in AML to address the importance of these ASXL1 mutations in the prognostic evaluation of AML.
目的:20q11上的ASXL1 (additional sex comb like 1)基因编码ASXL1蛋白,ASXL1蛋白属于参与基因表达和表观遗传调控的蛋白复合物。ASXL1位于DNMT3B基因附近,是与果蝇Asx基因同源的三个基因(ASXL1, ASXL2, ASXL3)家族的一部分。ASXL1基因共包含14个外显子,在绝大多数造血细胞类型中表达。虽然ASXL1在正常造血中的具体作用以及突变的ASXL1参与造血恶性肿瘤的进展尚未完全阐明,但目前的数据研究表明ASXL1具有肿瘤抑制基因的特征。ASXL1基因突变在髓系恶性肿瘤中被观察到,通常与侵袭性和不良临床结果相关,并于2009年首次在骨髓增生异常综合征(MDS)中被报道。然而,在核型正常的急性髓性白血病(AML)、骨髓增生异常相关改变的AML和非特征性细胞遗传学发现的AML中也发现ASXL1基因突变。在此,我们研究了ASXL1基因在AML中的参与,以解决这些ASXL1突变在AML预后评估中的重要性。